ZNF660

Across TCGA pan-cancer cohorts, ZNF660 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF660 data layer compared with 25 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ZNF660 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF660 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, ESCA, and PRAD are the cancer types where ZNF660 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.068	0.830	<.001	30	view →
ESCA	DFS	Median	All	0.098	0.533	.003	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
LIHC	DFS	Median	III,IV	0.046	0.361	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.922	0.482	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF660–CESC (OS)

Open the CESC breakdown →